AbbVie Inc. is an American biopharmaceutical company. It was founded in 2013 after Abbott Laboratories split into two separate companies. In the same year, AbbVie Inc. was listed on the New York Stock Exchange as a separate company under the ABBV ticker.

The company’s mission is to develop and deliver innovative medicines that solve serious health issues. Since its foundation, the company has invested more than $50 billion in the research and development of world-class medicines.

Nowadays, it employs more than 50,000 people worldwide. Its production facilities and research centers are located in 20 countries.

In 2021, the company's total revenue amounted to $56.2 billion. AbbVie's GAAP net profit for the 6 months of 2022 totaled $5.42 billion, an increase of 25.4% compared to $4.32 billion in the previous year. Its revenue jumped by 4.3% to $28.12 billion against $26.97 billion a year earlier.

AbbVie Inc. shares and factors impacting their price

Currently, the company's shares are traded between $140-145, which is four times higher since its IPO 10 years ago. Over the past year, the stock price has fluctuated in the range of $106.86 -$175.91.

Its shares are growing slowly but surely without sharp price swings. Thus, the purchase of AbbVie Inc. stock can be deemed a good long-term investment.

AbbVie allocates 45-50% of available funds annually to pay dividends to its shareholders. The amount of dividends is quite decent. For this reason, the company is classified as a dividend aristocrat.